Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.Abstract:
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...read more
Citations
More filters
Journal ArticleDOI
Monitoring chemotherapy and radiotherapy of solid tumors.
Wolfgang Weber,Hinrich Wieder +1 more
TL;DR: Early prediction of tumor response to chemotherapy and radiotherapy by FDG-PET has enormous potential to “personalize” treatment and to reduce the side-effects and costs of ineffective therapy.
Book ChapterDOI
The role of radiotherapy in oseosarcoma.
TL;DR: Radiotherapy is an important option as local treatment of unresectable tumors, following intralesional resection, or as palliation of symptomatic metastases as well as the combination of surgery, radiotherapy, and chemotherapy can be curative.
Journal ArticleDOI
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
TL;DR: Nine lncRNAs (91H, BCAR4, FGFR3-AS1, HIF2PUT, HOTTIP, HULC, MALAT-1, TUG1, UCA1), two of which are upregulated and considered oncogenic for osteosarcoma, and two which are downregulated and as tumor suppressor for the disease are identified.
Journal ArticleDOI
Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group.
Sven Jasnau,Ulrich Meyer,Jenny Potratz,Gernot Jundt,Matthias Kevric,Ulrich Joos,Heribert Jürgens,Stefan S. Bielack +7 more
TL;DR: Extragnathic sites and failure to achieve and maintain local surgical control emerged as strong negative prognostic factors for patients with craniofacial osteosarcoma andMultidisciplinary treatment of CFOS within a multicenter setting resulted in long-term survival in well over two thirds of affected patients.
Journal ArticleDOI
Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.
Yuan Wang,Li Zhang,Xifu Zheng,Weiliang Zhong,Xiliang Tian,Baosheng Yin,Kang Tian,Weiguo Zhang +7 more
TL;DR: It is demonstrated that LINC00161 is an essential regulator in cisplatin-induced apoptosis, and the L INC00161-miR-645-IFIT2 signalling axis plays an important role in reducing osteosarcoma chemoresistance.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.